Loading...
•
Sep 30, 2023
Carisma Therapeutics Q3 2023 Earnings Report
Carisma Therapeutics reported financial results for the third quarter of 2023 and highlighted recent business updates.
Key Takeaways
Carisma Therapeutics reported its Q3 2023 financial results, highlighting advancements in clinical and pre-clinical programs, including data from the Phase 1 clinical study of CT-0508 and pre-clinical work with Moderna. The company's cash, cash equivalents, and marketable securities are expected to fund operations into the first quarter of 2025.
Presented updated data from Phase 1 clinical trial of CT-0508 at CAR-TCR Summit.
Selected clinical candidate for CT-1119, an anti-mesothelin CAR-Monocyte.
Presented pre-clinical proof of concept data of in vivo CAR-M from the collaboration with Moderna at SITC.
Cash, cash equivalents and marketable securities of $94.1 million are expected to fund the company into the first quarter of 2025.
Carisma Therapeutics
Carisma Therapeutics
Forward Guidance
Carisma Therapeutics believes its current cash, cash equivalents, and marketable securities will sustain planned operations into the first quarter of 2025.